Abivax SA Sponsored ADR (NASDAQ:ABVX) Sees Significant Drop in Short Interest

Abivax SA Sponsored ADR (NASDAQ:ABVX – Get Free Report) was the recipient of a significant decline in short interest during the month of October. As of October 30th, there was short interest totaling 4,110,784 shares, a decline of 43.3% from the October 15th total of 7,254,941 shares. Based on an average daily volume of 888,647 shares, the short-interest ratio is currently 4.6 days. Currently, 4.7% of the shares of the company are short sold.

Analysts Set New Price Targets

Several equities analysts have weighed in on ABVX shares. Guggenheim restated a “buy” rating and set a $175.00 price objective on shares of Abivax in a research note on Tuesday, October 20th. Truist Financial lowered their price objective on shares of Abivax from $155.00 to $151.00 and set a “buy” rating on the stock in a research report on Tuesday, September 22nd. Morgan Stanley reissued an “overweight” rating and set a $180.00 price target on shares of Abivax in a research note on Friday, July 24th. Wedbush lowered their price target on Abivax from $118.00 to $96.00 and set a “neutral” rating for the company in a research report on Wednesday, October 21st. Finally, The Goldman Sachs Group assumed coverage on shares of Abivax in a research note on Wednesday, September 9th. They issued a “buy” rating and a $155.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Abivax presently has a consensus rating of “Moderate Buy” and an average price target of $155.00.

Check Out Our Latest Report on ABVX

Abivax Stock Up 2.1%

Shares of ABVX stock opened at $83.83 on Thursday. The firm has a market capitalization of $7.34 billion, a price-to-earnings ratio of -13.83 and a beta of 1.36. The firm has a fifty day moving average of $92.77 and a 200-day moving average of $112.09. Abivax has a 12-month low of $69.81 and a 12-month high of $148.83.

Abivax (NASDAQ:ABVX – Get Free Report) last released its quarterly earnings data on Monday, September 21st. The company reported ($1.71) earnings per share for the quarter, missing the consensus estimate of ($0.92) by ($0.79). The company had revenue of $1.37 million during the quarter, compared to analyst estimates of $0.80 million. Research analysts expect that Abivax will post -4.14 earnings per share for the current year.

Hedge Funds Weigh In On Abivax

Hedge funds and other institutional investors have recently modified their holdings of the stock. Two Seas Capital LP acquired a new position in shares of Abivax in the 3rd quarter valued at $66,996,000. Eversept Partners LP boosted its position in shares of Abivax by 42.0% in the 1st quarter. Eversept Partners LP now owns 934,423 shares of the company’s stock worth $104,048,000 after buying an additional 276,589 shares in the last quarter. Aberdeen Group plc raised its holdings in Abivax by 45.8% in the 3rd quarter. Aberdeen Group plc now owns 761,016 shares of the company’s stock valued at $75,356,000 after acquiring an additional 238,991 shares during the last quarter. Bank of America Corp DE increased its stake in Abivax by 40.9% during the first quarter. Bank of America Corp DE now owns 735,729 shares of the company’s stock worth $81,923,000 after acquiring an additional 213,440 shares during the last quarter. Finally, Janus Henderson Group PLC increased its position in shares of Abivax by 31.6% in the 1st quarter. Janus Henderson Group PLC now owns 878,829 shares of the company’s stock worth $98,007,000 after purchasing an additional 211,068 shares during the last quarter. Institutional investors own 47.91% of the company’s stock.

Abivax Company Profile

(Get Free Report)

Abivax is a clinical-stage biopharmaceutical company headquartered in Paris, France. It develops treatments for chronic inflammatory diseases, with a focus on therapies that regulate the body’s immune response. The company’s lead candidate, obefazimod (formerly known as ABX464), is an oral small molecule being studied for ulcerative colitis and other inflammatory conditions. It is designed to increase production of miR-124, a molecule involved in regulating inflammation. Founded in 2013, Abivax conducts clinical development internationally.

Recommended Stories

Receive News & Ratings for Abivax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abivax and related companies with MarketBeat.com's FREE daily email newsletter.